| Fiscal period | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Period End Date | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 |
|---|
| Revenues | -- | -- | -- | -- | -- | 2,066.74 | 1,838.71 | 1,678.91 | 1,554.97 | 1,514.46 |
| Revenue-Sleep and Respiratory Care products | 3,177.30 | 2,823.24 | 2,602.38 | 2,330.78 | 2,183.19 | -- | -- | -- | -- | -- |
| Revenue-Software as a Service | 400.83 | 373.59 | 354.63 | 275.79 | 157.00 | -- | -- | -- | -- | -- |
| Total Revenues | 3,578.13 | 3,196.83 | 2,957.01 | 2,606.57 | 2,340.20 | 2,066.74 | 1,838.71 | 1,678.91 | 1,554.97 | 1,514.46 |
| Cost of sales | -- | -- | -- | -- | -- | 864.99 | 772.22 | 667.52 | 565.19 | 573.80 |
| Voluntary product recall expenses | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of sales-Sleep and Respiratory Care products | 1,365.42 | 1,177.31 | 1,067.97 | 977.22 | 929.35 | -- | -- | -- | -- | -- |
| Cost of sales-Software as a Service | 148.75 | 135.29 | 121.66 | 92.76 | 48.68 | -- | -- | -- | -- | -- |
| Amortization of acquired intangible assets-Sleep and Respiratory Care products | 4.11 | 4.90 | 8.58 | 8.59 | 7.22 | -- | -- | -- | -- | -- |
| Amortization of acquired intangible assets-Software as a Service | 35.55 | 40.23 | 41.02 | 33.92 | 20.05 | -- | -- | -- | -- | -- |
| Gross Profit | 2,024.31 | 1,839.10 | 1,717.79 | 1,494.07 | 1,334.90 | 1,201.75 | 1,066.50 | 1,011.40 | 989.79 | 940.66 |
| Amortization of acquired intangible assets | 31.08 | 31.08 | 30.09 | 32.42 | 19.12 | 46.58 | 23.92 | 8.67 | 9.73 | 10.14 |
| Research and development | 253.58 | 225.28 | 201.95 | 180.65 | 155.15 | 144.47 | 118.65 | 114.87 | 118.23 | 120.12 |
| Education, research and settlement charge | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.77 |
| In-process research and development charge (note 20) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative | 739.37 | 670.39 | 676.69 | 645.01 | 600.37 | 553.97 | 488.06 | 478.63 | 450.41 | 430.80 |
| Restructuring expenses | -- | 8.67 | -- | 9.40 | 18.43 | 12.36 | 6.91 | -- | 6.33 | -- |
| Donations to Research Foundations | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Acquisition expenses | -- | -- | -- | (6.12) | -- | (10.08) | -- | -- | -- | -- |
| Litigation settlement expenses | -- | -- | 0.60 | (41.20) | -- | (8.50) | -- | -- | -- | -- |
| Total Operating Expenses | 1,024.03 | 935.42 | 908.13 | 914.81 | 793.07 | 775.95 | 637.55 | 602.16 | 584.70 | 585.83 |
| Operating Income (Loss) | 1,000.29 | 903.68 | 809.66 | 579.26 | 541.83 | 425.80 | 428.95 | 409.24 | 405.09 | 354.82 |
| Interest expense | 22.31 | 23.63 | 39.36 | 36.16 | 28.36 | 28.24 | 11.21 | 5.78 | 6.13 | 6.39 |
| Loss attributable to equity method investments | (8.49) | (11.21) | (25.06) | (15.83) | -- | -- | -- | -- | -- | -- |
| Gain (loss) on equity investments (note 5) | (12.20) | 14.52 | (14.52) | -- | -- | -- | -- | -- | -- | -- |
| Interest income (expense), net | -- | -- | -- | 2.30 | 16.38 | 17.09 | 16.86 | 26.21 | 31.24 | 38.87 |
| Other, net | 3.20 | 0.30 | 2.36 | (10.73) | (8.54) | 4.10 | 4.96 | 6.25 | 0.88 | (2.19) |
| Gain (loss) on extinguishment of debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Government grants | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: License fees | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Gain/(loss) on foreign currency hedging position | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Gain/(loss) on foreign currency transactions | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Other | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Realized gain on sale of marketable securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Impairment of cost method investment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Gain on sale of real property | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Gain on sale of plant and equipment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other: Gain on sale of business assets and contracts | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total other income (expenses), net | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pre-Tax Income - U.S | (85.92) | 71.87 | 60.55 | (34.47) | 42.63 | (4.99) | 1.79 | 11.43 | -- | -- |
| Non-U.S | 1,046.40 | 811.80 | 672.54 | 553.32 | 478.69 | 423.73 | 437.78 | 424.49 | -- | -- |
| Income before Income taxes | 960.48 | 883.66 | 733.09 | 518.85 | 521.31 | 418.74 | 439.57 | 435.92 | 431.08 | 385.12 |
| Current: Federal | 4.38 | (115.11) | 9.79 | 28.66 | 128.97 | 16.47 | 24.33 | 28.43 | 18.93 | 42,065.00 |
| Current: State | 10.70 | 9.04 | 6.90 | 7.60 | 0.95 | (1.16) | 5.81 | 0.70 | 1.33 | 888.00 |
| Deferred: Federal | (12.61) | (22.79) | (13.00) | (30.46) | 9.49 | 11.39 | 5.64 | (4.27) | (0.42) | (1,345.00) |
| Deferred: State | (2.77) | (4.21) | (3.34) | (5.41) | (0.35) | 2.71 | (1.64) | (0.18) | (0.08) | (264.00) |
| Current- Non-U.S | 177.79 | 531.81 | 124.60 | 127.54 | 68.86 | 65.61 | 58.02 | 50.89 | 55.68 | 53,713.00 |
| Deferred- Non-U.S | 3.57 | 10.41 | (13.54) | (13.67) | (2.19) | (18.55) | (4.99) | 7.46 | 10.37 | (17,071.00) |
| Income taxes | 181.05 | 409.16 | 111.41 | 114.26 | 205.72 | 76.46 | 87.16 | 83.03 | 85.81 | 77.99 |
| Net Income (Loss) Available to Common Shareholders | 779.44 | 474.51 | 621.67 | 404.59 | 315.59 | 342.28 | 352.41 | 352.89 | 345.27 | 307.13 |
| Continuing Operations- (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Basic Earnings Per Share | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 | 2.51 | 2.51 | 2.44 | 2.15 |
| Continuing Operations- (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diluted Earnings Per Share | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 | 2.49 | 2.47 | 2.39 | 2.10 |
| Weighted Average Shares Outstanding (Basic) | 146.07 | 145.31 | 144.34 | 143.11 | 142.76 | 141.36 | 140.24 | 140.47 | 141.47 | 142.95 |
| Weighted Average Shares Outstanding (Diluted) | 147.04 | 146.45 | 145.65 | 144.48 | 143.99 | 142.45 | 141.67 | 142.69 | 144.36 | 146.41 |